title: ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy.
abstract: Prevention of diabetes represents an important therapeutic goal in current cardiovascular risk reduction strategies. Blockade of the renin-angiotensin system has been shown to markedly reduce the incidence of new-onset diabetes in different patient populations. Recent results from three large clinical endpoint trials with the angiotensin-II receptor blocker telmisartan regarding new-onset diabetes, atrial fibrillation, and left ventricular hypotrophy will be discussed.
authors.affiliation: Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany. ulrich.kintscher@charite.de
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kintscher
mesh_terms: D001281:Atrial Fibrillation / Q000150:complications*; D048909:Diabetes Complications; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications*; D012084:Renin-Angiotensin System